Evidence map›Paper›PMID 38934617›Full record

ArticlemBio2024

Type III interferon drives pathogenicity to

Silvia Pires, Katherine Kaiser, Dane Parker

Abstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Microbiota-dependent IFN-L controls uterine and placental immunity.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Silvia PiresDepartment of Pathology, Immunology and Laboratory Medicine, Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Katherine KaiserDepartment of Pathology, Immunology and Laboratory Medicine, Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Dane ParkerDepartment of Pathology, Immunology and Laboratory Medicine, Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, New Jersey, USA.ORCID 0000-0001-7304-3392

Funding

ROLE OF TYPE III INTERFERONS IN STAPHYLOCOCCUS AUREUS RESPIRATORY TRACT INFECTIONR01HL134870 · NHLBI · RBHS-NEW JERSEY MEDICAL SCHOOL · PI PARKER, DANE · 2017 to 2020
$1.8M
HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL134870NHLBI NIH HHS R01 HL134870
6 · The paper itself

Abstract

Type III interferon signaling contributes to the pathogenesis of the important human pathogen

Indexed as

InterferonsMacrophages, AlveolarMice, KnockoutStaphylococcal InfectionsStaphylococcus aureusAnimalsHost-Pathogen InteractionsInterferon LambdaMiceMice, Inbred C57BLReceptors, InterferonRespiratory MucosaSignal TransductionVirulenceIFNLR1 protein, mouseInterferon LambdaInterferonsReceptors, InterferonairwayinterferonslungStaphylococcus aureustype III interferon

Identifiers

PMID38934617
PMCPMC11253584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.